Matches in Wikidata for { <http://www.wikidata.org/entity/Q74277274> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q74277274 description "clinical trial" @default.
- Q74277274 description "ensayu clínicu" @default.
- Q74277274 description "klinisch onderzoek" @default.
- Q74277274 description "клінічне випробування" @default.
- Q74277274 name "Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)" @default.
- Q74277274 name "Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma" @default.
- Q74277274 type Item @default.
- Q74277274 label "Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)" @default.
- Q74277274 label "Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma" @default.
- Q74277274 prefLabel "Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)" @default.
- Q74277274 prefLabel "Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma" @default.
- Q74277274 P1050 Q74277274-F66359E2-46DA-4053-AF7F-401F12802E00 @default.
- Q74277274 P1132 Q74277274-CE2D6C5D-4C6B-49CE-AD95-8E7A5B168B33 @default.
- Q74277274 P1476 Q74277274-A7EA2B59-0F34-4CC0-8F9A-6E687C2D1B12 @default.
- Q74277274 P17 Q74277274-24E549AD-3DCA-4550-B7DB-526030FDBDA4 @default.
- Q74277274 P17 Q74277274-9F425EB7-30D0-4F8A-AB15-49A5A6D40D8A @default.
- Q74277274 P17 Q74277274-EC775026-CE06-4C1D-AA5B-87E9CB2FC890 @default.
- Q74277274 P2899 Q74277274-EF65ED50-BA59-4AEF-B0AB-C8AB4404E036 @default.
- Q74277274 P3098 Q74277274-00D2473A-3FFF-4CF2-A6A0-FEA008CA7C35 @default.
- Q74277274 P31 Q74277274-48A5AAF5-7E0A-4E83-B3F9-3A2E2239855E @default.
- Q74277274 P580 Q74277274-0B098E7E-EDD1-4F64-9AC8-3C14C3F0657E @default.
- Q74277274 P582 Q74277274-C7909F05-7F7B-4708-8759-920111FA598E @default.
- Q74277274 P6099 Q74277274-A45F84DF-E315-4F93-B164-76C66AF7295C @default.
- Q74277274 P8363 Q74277274-08B97B38-2876-4213-8C08-893842AEA5BB @default.
- Q74277274 P859 Q74277274-A6F41944-39DE-415F-9172-0990C9252EB3 @default.
- Q74277274 P1050 Q467635 @default.
- Q74277274 P1132 "+464" @default.
- Q74277274 P1476 "A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5" @default.
- Q74277274 P17 Q16 @default.
- Q74277274 P17 Q29 @default.
- Q74277274 P17 Q408 @default.
- Q74277274 P2899 "+18" @default.
- Q74277274 P3098 "NCT04126200" @default.
- Q74277274 P31 Q30612 @default.
- Q74277274 P580 "2019-10-07T00:00:00Z" @default.
- Q74277274 P582 "2025-02-21T00:00:00Z" @default.
- Q74277274 P6099 Q42824440 @default.
- Q74277274 P8363 Q78089383 @default.
- Q74277274 P859 Q212322 @default.